Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

IPO/Stock Watch

Market trends, bell-weather stocks, filings and IPOs...

Gland Pharma, Fosun's Indian Subsidiary, Approved for $814 Million IPO

Shanghai's Everest Medicines Stages $451 Million Hong Kong IPO

Genor Completes $371 Million Hong Kong IPO; Market Cap Reaches $1.8 Billion

Zai Lab Raises $761 Million in Hong Kong IPO; Climbs 8.5% Higher

Genor Bio Conducting $370 Million IPO in Hong Kong

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020